Berry Pigment C3G Shrinks Myeloma Tumors by Stripping Away Immune Shields
Cyanidin-3-O-glucoside, a natural anthocyanin, reduces immunosuppressive Tregs and slows multiple myeloma growth in mice and cell studies.
Summary
Cyanidin-3-O-glucoside (C3G), a pigment found in berries and a known CD38 enzyme inhibitor, was tested as a potential multiple myeloma (MM) therapy. In MM-bearing mice, C3G nearly halved tumor weight and selectively reduced regulatory T cells (Tregs) in peripheral blood without affecting other lymphocyte subsets. In vitro, C3G dose-dependently reduced Tregs derived from healthy human CD4+ T cells, even in the presence of MM cells. Network pharmacology and RNA sequencing pointed to downregulation of granzyme B (GZMB) and upregulation of heme oxygenase 1 (HMOX1) as key transcriptional mechanisms. These findings suggest C3G may restore anti-tumor immunity in MM by dismantling the immunosuppressive tumor microenvironment.
Detailed Summary
Multiple myeloma (MM) remains incurable, and its tumor immune microenvironment (TIME) is heavily skewed toward immune suppression. Regulatory T cells (Tregs) are central to this suppression—they block effector T and NK cells, promote myeloid-derived suppressor cells, and correlate with worse survival in MM patients. Anti-CD38 monoclonal antibodies like daratumumab partially work by eliminating CD38+ Tregs, which are more potently immunosuppressive than their CD38-negative counterparts. Cyanidin-3-O-glucoside (C3G), the primary anthocyanin in dark berries, is a natural CD38 enzymatic inhibitor, raising the question of whether it can mimic this Treg-depleting mechanism.
Researchers established subcutaneous MM xenograft models in mice (using MM.1S cells) and treated animals with C3G or PBS control. By day 13, C3G-treated tumors were roughly half the volume of controls (528 vs. 1037 mm³, P<0.01), and final tumor weights were reduced by more than 55% (508 vs. 1157 mg, P<0.001). Flow cytometry of peripheral blood showed C3G selectively reduced CD4+CD25+FoxP3+ Tregs in both healthy and MM-bearing mice, without significantly altering T cells, B cells, or NK cell proportions. Immunofluorescence confirmed fewer Foxp3+CD4+ tumor-infiltrating Tregs in treated animals.
In vitro, naive human CD4+ T cells from healthy donors were treated with escalating C3G concentrations (0–400 µM). C3G reduced Tregs in a concentration-dependent manner—from ~29% at baseline to ~1% at 400 µM—without significant cytotoxicity at or below 400 µM. Critically, C3G maintained this Treg-reducing effect even when CD4+ T cells were co-cultured directly with MM.1S or RPMI-8226 MM cells. Pre-treating MM cells with C3G before co-culture did not affect Treg levels, indicating C3G acts directly on T cells rather than through MM cells. C3G also increased Th1 and Th2 cell levels, suggesting a broader shift toward pro-immune phenotypes.
To identify mechanisms, the team combined network pharmacology (41 overlapping targets between C3G predicted targets and Treg-related genes) with RNA sequencing of C3G-treated CD4+ T cells. Network analysis highlighted 13 core genes including AKT1, STAT3, BCL2, HIF1A, and TNF, with KEGG pathways enriched in apoptosis, HIF-1 signaling, PD-L1/PD-1, and Th17 differentiation. RNA-seq revealed that among the 41 candidate targets, granzyme B (GZMB) was significantly downregulated and heme oxygenase 1 (HMOX1) was significantly upregulated following C3G treatment, findings validated by real-time PCR. GZMB, expressed by Tregs, normally kills effector T cells; its suppression by C3G-mediated CD38 inhibition may be the primary molecular lever reducing Treg survival and function.
These results position C3G as a naturally derived immunomodulatory agent capable of reshaping the MM tumor microenvironment. Its dual action—direct Treg reduction and potential CD38 inhibition—parallels the immunological mechanism of daratumumab but through a small-molecule, orally bioavailable compound. However, the work is early-stage, and translation to clinical use will require extensive pharmacokinetic, toxicology, and human trial data.
Key Findings
- C3G reduced MM tumor weight by >55% in mice compared to untreated controls (P<0.001).
- C3G selectively lowered Treg proportions in peripheral blood without affecting T, B, or NK cells.
- In vitro, 400 µM C3G dropped Tregs from ~29% to ~1% in a concentration-dependent manner.
- C3G retained Treg-reducing activity even when CD4+ T cells were co-cultured with MM cells.
- RNA-seq identified GZMB downregulation and HMOX1 upregulation as key transcriptional mechanisms.
Methodology
Subcutaneous MM xenograft mouse models (MM.1S cells) were treated with C3G or PBS, with tumor growth monitored by caliper and immune subsets by flow cytometry. In vitro studies used sorted naive human CD4+ T cells co-cultured with MM cell lines and treated with C3G up to 400 µM. Mechanistic exploration combined network pharmacology (six target databases, PPI network analysis) with RNA sequencing, validated by real-time PCR.
Study Limitations
The mouse model used immunocompromised hosts with human MM cell xenografts, limiting full immune system interaction assessment. In vitro concentrations (400 µM) may not be achievable in human plasma after oral C3G dosing given known poor bioavailability of anthocyanins. The study lacks mechanistic confirmation via GZMB or HMOX1 knockout/overexpression experiments, and no human clinical data are presented.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.